Clinical trials: Esophagogastric Cancer
Solid Tumor, Gastric Cancer
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT04400383
- Testing
- AB011 Injection
- Where
- 12 sites in China
- Volunteers
- 62 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
This is an open-label, single-arm, single-center clinical study to investigate the safety and efficacy of fuquinitinib combined with PD-1 inhibitors and first-line chemotherapy in the treatment of inoperable HER2-negative…
- Trial name
- G/GEJ cancer (NCT06158919)
- Testing
- Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Gastric Cancer
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
Gastric cancer remains a significant global public health problem. Although in developed countries its incidence has dramatically decreased, on a worldwide scale it is still a leading cause of cancer-related deaths.
- Trial name
- TOPGEAR (NCT01924819)
- Testing
- Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel, Preoperative chemoradiotherapy, Gastric resection
- Where
- 59 sites in Australia, Belgium and 8 more
- Volunteers
- 574 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Adenocarcinoma, Stomach Cancer
Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach
This prospective study includes patients with histologically proven cancer of the esophagogastric junction (Siewert Type II and III) and the stomach.
- Conditions
- Adenocarcinoma, Stomach Cancer, Cancer of Esophagogastric Junction
- Trial name
- NCT00800969
- Testing
- FDG-PET-CT
- Where
- Switzerland
- Sponsor
- University of Zurich
Gastric and Esophagogastric Junction Adenocarcinoma
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma…
- Trial name
- VESTIGE (NCT03443856)
- Testing
- Nivolumab and Ipilimumab, chemotherapy
- Where
- 28 sites in Czechia, France and 7 more
- Volunteers
- 197 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Gastric Cancer, Siewert Type III Adenocarcinoma of Esophagogastric Junction
Postoperative Morbidity and Mortality After Gastric Cancer Surgery
Gastric cancer is still one of the main health care issue and gastrectomy with lymph node dissection is the only chance to be cure.
- Conditions
- Gastric Cancer, Siewert Type III Adenocarcinoma of Esophagogastric Junction, Stomach Cancer
- Trial name
- GASTROSTAT (NCT06277908)
- Testing
- Elective Surgery for gastric cancer
- Where
- 9 sites in Russia
- Volunteers
- 700 people
- Sponsor
- P. Herzen Moscow Oncology Research Institute
Gastric Cancer, Esophagogastric Junction Cancer
Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
For locally advanced esophagogastric junction and gastric cancer, neoadjuvant chemotherapy can downstage T and N stage,treated distant micrometastases early , and finally improve the long-term survival.
- Trial name
- NCT06310473
- Testing
- Cadonilimab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative chemotherapy with FLOT regimen and trastuzumab in combination with toripalimab in…
- Conditions
- Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer
- Trial name
- NCT05715931
- Testing
- Toripalimab, Trastuzumab, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)
- Where
- 8 sites in China
- Volunteers
- 30 people
- Sponsor
- Yu jiren
Oesophageal Cancer, Gastric Cancer
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
The aim of the project is to demonstrate superior detection ratio of [18F]AlF-FAPI-74 PET/CT compared to [18F]FDG PET/CT or conventional imaging in treatment-naïve, newly diagnosed patients with oesophagogastric adenocarcinoma…
- Conditions
- Oesophageal Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma, FAP
- Trial name
- FAPIDO (NCT06782412)
- Testing
- [18F]AlF-FAPI-74 PET/CT
- Where
- 3 sites in Belgium
- Volunteers
- 109 people
- Sponsor
- KU Leuven
Patient Reported Outcome Measures, Colorectal Cancer
Predicting Disease Progression and/or Recurrence in Cancer
This is a prospective study addressing the challenge of predicting disease progression and/or recurrence in patients diagnosed with metastatic colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer…
- Conditions
- Patient Reported Outcome Measures, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer
- Trial name
- NCT04776837
- Testing
- Observational Cohort
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Massachusetts General Hospital
Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
The purpose of this study is to evaluate the safety and efficacy of S-1 and Cisplatin compared to 5-FU and Cisplatin in treatment of patients with metastatic diffuse gastric and gastro-esophageal junction cancer previously…
- Trial name
- DIGEST (NCT01285557)
- Testing
- S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm), Fluorouracil/cisplatin (control arm)
- Where
- 87 sites in United States, Argentina and 18 more
- Volunteers
- 361 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction
Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA
The purpose of this study is to determine whether apatinib plus irinotecan can improve progression free survival compared with single irinotecan in patients with advanced gastric cancer or adenocarcinoma of esophagogastric…
- Trial name
- NCT03030937
- Testing
- Apatinib, Irinotecan
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Fujian Cancer Hospital
B Cell Lymphoma, B Cell Leukemia
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR T cells in patients with malignant tumors with positive antigen targets.
- Conditions
- B Cell Lymphoma, B Cell Leukemia, Myeloma, Hepatocellular Carcinoma
- Trial name
- NCT03302403
- Testing
- CAR-CD19 T cell, CAR-BCMA T cell, CAR-GPC3 T cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Kang YU
Gastroesophageal Adenocarcinoma
The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II):
The addition of immunotherapy to chemotherapy improves outcomes in patients with HER2-negative gastroesophageal adenocarcinoma (GEA), and investigators aim to explore its role in the perioperative setting.
- Trial name
- SCORPIO (NCT05986227)
- Testing
- toripalimab FOLFOX
- Volunteers
- 126 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Cancer, Adenocarcinoma of Esophagogastric Junction
Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
This study aims to assess the efficacy and safety of a combination therapy consisting of Anlotinib, TQB2450 (a PD-L1 inhibitor), and Albumin-bound Paclitaxel regimens in patients with advanced gastric cancer (GC) or…
- Trial name
- NCT06222944
- Testing
- Anlotinib, TQB2450, Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking University
Gastric Cancer, Metastatic
The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM
Gastric cancer (GC) with peritoneal metastasis has a poor prognosis and short survival. In recent years, heat intraperitoneal perfusion chemotherapy (HIPEC) has gained better efficacy in the treatment of peritoneal metastases of…
- Trial name
- NCT06427252
- Testing
- HIPEC, Systemic therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastroesophageal-junction Cancer
Significance of Peritoneal Washing Cytology Before and After Neoadjuvant Chemotherapy in Patients With Esophagogastric-junction Cancer
Background: The prevalence of gastroesophageal-junction cancer (cancer between the distal part of the oesophagus, and proximal part of the stomach/GEJ-cancer) is increasing in Denmark with more than 400 patients per year.
- Trial name
- NCT02085564
- Testing
- Peritoneal washing cytology
- Where
- Denmark
- Volunteers
- 87 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
The study is being conducted to evaluate the efficacy, safety and tolerability of radiotherapy and chemotherapy, apatinib with camrelizumab in the neoadjuvant (prior to surgery) and adjuvant (after surgery) treatment of…
- Trial name
- NCT07026149
- Testing
- Apatinib+Camrelizumab+SOX, Preoperative Radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Siewert Type II Adenocarcinoma of Esophagogastric Junction
Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma
To explore the 5-year overall survival (OS) of right versus left thoracic surgical approaches for patients with locally advanced Siewert II gastroesophageal junction adenocarcinoma treated by neoadjuvant chemotherapy
- Trial name
- NCT06644352
- Testing
- different thoracic surgical approaches
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
Study of FMT Combined With Nivolumab in Gastric Cancer
This study is a single-arm, single center study. The purpose of this study is to evaluate the efficacy and safety of FMT capsules XBI-302 combined with Nivolumab in the treatment of anti-PD-1/L1 resistant gastric cancer.
- Conditions
- Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma, Esophagus Adenocarcinoma
- Trial name
- NCT05001360
- Testing
- XBI-302 + Nivolumab
- Where
- China
- Sponsor
- Fujian Cancer Hospital